US7829595 — Rapid dissolution formulation of a calcium receptor-active compound
Method of Use · Assigned to Amgen Inc · Expires 2026-09-22 · 0y remaining
What this patent protects
This patent protects a method of manufacturing a pharmaceutical composition with a controlled dissolution profile for a calcium receptor-active compound.
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1098 |
— | cinacalcet-hydrochloride |
U-1098 |
— | cinacalcet-hydrochloride |
U-1098 |
— | cinacalcet-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.